MORRISVILLE, N.C., Oct. 26, 2011 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, announced today the launch of its new corporate websites, www.ncontactinc.eu and www.ncontactinc.com. The design of the new corporate sites reflects the evolution of nContact's technology and the market for treating cardiac arrhythmias that affect millions of people worldwide.
"The new websites are excellent educational references that highlight how our technology is being utilized in the clinical setting to reach new and previously underserved markets," said John P. Funkhouser, President and CEO of nContact. "This is an important step for our company that reflects our ever evolving technology and approach to expanding available treatments for a patient population who has historically had limited options."
The enhanced websites provide an in-depth view of nContact's Numeris™ and EPi-Sense™ Guided Coagulation Systems with VisiTrax®, expanded physician resources and detailed images and animation videos to build awareness among physicians and patients looking to explore options for the treatment of cardiac arrhythmias.
About nContact, Inc.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.
To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.
SOURCE nContact, Inc.